Literature DB >> 29633651

Age/disease duration influence on activities of daily living and quality of life after levodopa-carbidopa intestinal gel in Parkinson's disease.

Angelo Antonini1, Weining Z Robieson2, Lars Bergmann2, Ashley Yegin2, Werner Poewe3.   

Abstract

AIM: To determine if age and Parkinson's disease duration at therapy initiation influence the efficacy of levodopa-carbidopa intestinal gel (LCIG) on quality of life and activities of daily living. PATIENTS &
METHODS: This post hoc analysis assessed subgroups of patients stratified by baseline age, disease duration, hours/day of 'off' time and levodopa equivalent dose. Patients' data were collected from the GLORIA study, a 24-month observational registry evaluating long-term effectiveness of LCIG. RESULTS &
CONCLUSION: LCIG therapy led to sustained improvements in quality of life irrespective of patient age and disease duration at baseline. Improvements in activities of daily living were observed across all subgroups, particularly in younger patients, patients with shorter disease duration and in patients with the highest baseline levodopa equivalent dose.

Entities:  

Keywords:  activities of daily living; levodopa-carbidopa intestinal gel; quality of life

Mesh:

Substances:

Year:  2018        PMID: 29633651     DOI: 10.2217/nmt-2017-0046

Source DB:  PubMed          Journal:  Neurodegener Dis Manag        ISSN: 1758-2024


  6 in total

Review 1.  Apomorphine and levodopa infusion for motor fluctuations and dyskinesia in advanced Parkinson disease.

Authors:  Angelo Antonini; Bianca Nitu
Journal:  J Neural Transm (Vienna)       Date:  2018-07-13       Impact factor: 3.575

2.  Safety of Levodopa-Carbidopa Intestinal Gel Treatment in Patients with Advanced Parkinson's Disease Receiving ≥2000 mg Daily Dose of Levodopa.

Authors:  Cindy Zadikoff; Werner Poewe; James T Boyd; Lars Bergmann; Horia Ijacu; Pavnit Kukreja; Weining Z Robieson; Janet Benesh; Angelo Antonini
Journal:  Parkinsons Dis       Date:  2020-02-13

3.  Long-term effectiveness of levodopa-carbidopa intestinal gel on motor and non-motor symptoms in advanced Parkinson's disease: results of the Italian GLORIA patient population.

Authors:  Angelo Antonini; Pietro Marano; Graziano Gusmaroli; Nicola Modugno; Claudio Pacchetti; Mariachiara Sensi; Gabriella Melzi; Lars Bergmann; Maurizio Zibetti; Leonardo Lopiano
Journal:  Neurol Sci       Date:  2020-04-28       Impact factor: 3.307

4.  Off Time Independently Affects Quality of Life in Advanced Parkinson's Disease (APD) Patients but Not in Non-APD Patients: Results from the Self-Reported Japanese Quality-of-Life Survey of Parkinson's Disease (JAQPAD) Study.

Authors:  Yuka Hayashi; Ryoko Nakagawa; Miwako Ishido; Yoko Yoshinaga; Jun Watanabe; Kanako Kurihara; Koichi Nagaki; Hiromu Ogura; Takayasu Mishima; Shinsuke Fujioka; Yoshio Tsuboi
Journal:  Parkinsons Dis       Date:  2021-10-12

5.  The Effects of Non-Invasive Brain Stimulation on Quantitative EEG in Patients With Parkinson's Disease: A Systematic Scoping Review.

Authors:  Thaísa Dias de Carvalho Costa; Clécio Godeiro Júnior; Rodrigo Alencar E Silva; Silmara Freitas Dos Santos; Daniel Gomes da Silva Machado; Suellen Marinho Andrade
Journal:  Front Neurol       Date:  2022-03-02       Impact factor: 4.003

6.  Advanced Parkinson's Disease Treatment Simplification and Long-Term Outcomes with Levodopa Carbidopa Intestinal Gel: COSMOS Romanian Subanalysis.

Authors:  Mihaela Adriana Simu; Dragoș Cătălin Jianu; Adriana Octaviana Dulamea; Viorelia Adelina Constantin; Diana Popescu; Juan Carlos Parra; József Attila Szász
Journal:  Brain Sci       Date:  2021-11-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.